Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in Aktien #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Aktienkurs
$0.00185055
Marktkapitalisierung
$48.29K
Veränderung (1 Tag)
-3.55%
Veränderung (1 Jahr)
30.31%
Land
GB
Handel Nuformix plc (NFX)

Kategorie

Healthcare
P/S-Verhältnis für Nuformix plc (NFX)
P/S-Verhältnis zum September 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Nuformix plc beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.00. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für Nuformix plc von 2014 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 116.70 74.68%
2021 66.81 87.30%
2020 35.67 81.62%
2019 19.64 -95.96%
2018 485.61 0.00%
2017 0.00 -100.00%
2016 2.23 0.00%
2014 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH